Atopic Dermatitis First Line Treatment Options: Systemic Therapies for Moderate-to-Severe AD

Experts in dermatology discuss the rapidly expanding treatment landscape of atopic dermatitis and how these new treatment options have changed the management of AD.

Andrew Blauvelt, MD, MBA, reviews systemic vs topical treatment of AD, discussion patient preferences as a factor for treatment selection.

Expert dermatologists discuss treatment selection for short-term rescue vs long-term maintenance therapy.

Experts in dermatology comment on how often quickness of response to therapy determines treatment selection for teenaged patients with AD.

Jonathan I Silverberg, MD, PhD, MPH; Elizabeth Swanson, MD; Brad Glick, DO, MPH, FAOCD; and Andrew Blauvelt, MD, MBA, review factors that lead to switching therapies in AD, focusing on monotherapies vs combination therapy.

Expert dermatologists present and share initial impressions of a patient case for a 6-year-old male with AD, highlighting the impact of sleep deprivation.

Elizabeth Swanson, MD, and Brad Glick, DO, MPH, FAOCD, share treatment approaches for pediatric patients with AD.

Expert dermatologists review the use of dupilumab for the treatment of AD, focusing on the once-monthly shot as a factor in selection.

Experts in dermatology review clinical trials for AD treatment and how this data translates into their own practices.

Elizabeth Swanson, MD; Brad Glick, DO, MPH, FAOCD; and Andrew Blauvelt, MD, MBA, highlight treatment options for a specific patient with AD, focusing on dupilumab.

Jonathan I Silverberg, MD, PhD, MPH; Elizabeth Swanson, MD; Brad Glick, DO, MPH, FAOCD; and Andrew Blauvelt, MD, MBA, discuss their initial impressions of an adolescent patient with AD, focusing on systemic therapy.

Experts in dermatology review recommendations for systemic therapies and JAK inhibitors in the management of AD and other factors that guide treatment selection.

Elizabeth Swanson, MD, shares pearls on how to communicate with AD patients who are uncertain about treatment through self-administered injection.

Expert dermatologists review a final case about a 32-year-old male with AD, highlighting systemic therapy as first-line treatment.

Four dermatologists from across the country discuss the widened armamentarium of AD treatments in a recent Around the Practice series.

Four clinicians discuss the widening landscape of systemic therapies for patients with atopic dermatitis.